Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Allianz Asset Management GmbH

Key Points

• Allianz Asset Management GmbH increased its investment in Insmed, Inc. by 4.9%, acquiring an additional 3,534 shares, bringing its total holdings to 75,284 shares worth approximately $5.74 million.
• Insider activity reported includes the sale of nearly 606,597 shares by company insiders worth over $55 million, indicating a significant decrease in their stock ownership.
• Insmed, Inc. reported a net loss per share of ($1.42) for the recent quarter, missing analysts' expectations, but revenue increased by 22.9% year-over-year to $92.82 million.

Allianz Asset Management GmbH boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 4.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,284 shares of the biopharmaceutical company's stock after acquiring an additional 3,534 shares during the quarter. Allianz Asset Management GmbH's holdings in Insmed were worth $5,743,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Cullen Frost Bankers Inc. raised its holdings in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP purchased a new position in shares of Insmed during the fourth quarter valued at approximately $28,000. NBC Securities Inc. acquired a new position in Insmed during the first quarter worth approximately $49,000. Versant Capital Management Inc lifted its position in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 590 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after buying an additional 325 shares during the last quarter.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 9,925 shares of Insmed stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $65.47, for a total value of $649,789.75. Following the completion of the sale, the insider owned 86,596 shares of the company's stock, valued at $5,669,440.12. The trade was a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 599,767 shares of company stock valued at $54,625,108. 3.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently commented on INSM shares. Mizuho raised their price target on shares of Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. Wells Fargo & Company increased their price objective on Insmed from $119.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, July 22nd. Bank of America lifted their price objective on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, Morgan Stanley upped their price objective on Insmed from $102.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $109.20.

Insmed Stock Up 2.5%

Shares of Insmed stock traded up $2.60 during trading hours on Thursday, reaching $107.78. The company's stock had a trading volume of 561,364 shares, compared to its average volume of 2,754,226. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. Insmed, Inc. has a one year low of $60.40 and a one year high of $108.42. The company has a market capitalization of $20.45 billion, a P/E ratio of -18.12 and a beta of 0.90. The stock's fifty day simple moving average is $92.76 and its two-hundred day simple moving average is $80.50.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter in the prior year, the company posted ($1.06) EPS. Insmed's revenue was up 22.9% on a year-over-year basis. On average, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.